A fixed-dose combination of a first-generation ethanolamine-class antihistamine (Doxylamine) and a water-soluble B-complex vitamin (Pyridoxine). Primarily indicated for the management of nausea and vomiting in pregnancy (NVP), specifically for cases unresponsive to conservative management. Doxylamine provides central antiemetic and sedative effects via histamine H1 receptor antagonism, while Pyridoxine may help correct a relative deficiency and modulate neurotransmitter pathways involved in nausea. This combination is considered a first-line pharmacological therapy for NVP in many international and Indian guidelines, based on extensive safety data.
Adult: For NVP: The typical regimen is 2 tablets at bedtime (40 mg doxylamine + 40 mg pyridoxine). If symptoms persist into the day, the dose can be split: 1 tablet in the morning and 2 tablets at bedtime. Maximum daily dose: 4 tablets (80 mg doxylamine + 80 mg pyridoxine). Always start at the lowest effective dose.
Note: Oral administration. Can be taken with or without food. Taking with a light snack may reduce gastric irritation. Swallow whole with a glass of water. The bedtime dose is critical for controlling morning nausea. Do not crush or chew unless advised (some brands may offer dispersible tablets).
The combination works synergistically. Doxylamine succinate is a potent histamine H1 receptor antagonist. Its antiemetic effect is primarily mediated through central antagonism at the H1 receptors in the chemoreceptor trigger zone (CTZ) and the vestibular apparatus, reducing the stimulation that leads to nausea and vomiting. Pyridoxine (Vitamin B6) is a cofactor in multiple enzymatic reactions involved in the synthesis of neurotransmitters like GABA, serotonin, and dopamine. In NVP, it may help by modulating these neurotransmitter pathways in the CTZ and correcting a relative functional deficiency that may contribute to nausea.
Pregnancy: Pregnancy Category A (US FDA). Extensive human data from the Canadian 'Diclectin/Bendectin' experience and subsequent studies show no increased risk of major malformations when used in recommended doses for NVP. Considered first-line pharmacotherapy for NVP. Use should be for clear medical indication at the lowest effective dose.
Driving: STRONGLY DISCOURAGED. Doxylamine causes significant drowsiness and impairs cognitive and motor functions. Patients must not drive or operate heavy machinery until their individual response is known, which may take several days.
| CNS Depressants (Alcohol, Benzodiazepines, Opioids, Barbiturates) | Additive CNS depression, profound sedation, impaired psychomotor performance. | Major |
| Anticholinergic Drugs (Atropine, TCAs, Antipsychotics) | Additive anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, confusion). | Major |
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Tranylcypromine | Exaggerated anticholinergic and CNS depressant effects; can cause hypertensive crisis. | Contraindicated |
| Levodopa | Pyridoxine at high doses can accelerate peripheral metabolism of levodopa, reducing its efficacy. Not significant at 20mg dose. | Moderate (for high-dose B6) |
| Phenytoin | Pyridoxine may increase the hepatic metabolism of phenytoin, potentially decreasing its serum levels. | Moderate |